1. Atorvastatin ameliorates depressive behaviors and neuroinflammatory in streptozotocin-induced diabetic mice
- Author
-
Liang Jing, Xu Lei-Mei, Ye-Zi, Yang Fan, Cao Yan-Cheng, Sun Ruo-Lan, Yu Xu-Ben, Wang Ye-Xuan, Tang Cong-Rong, and Zhang Hai-Na
- Subjects
Male ,Atorvastatin ,Anti-Inflammatory Agents ,Prefrontal Cortex ,Pharmacology ,Hippocampus ,Streptozocin ,Diabetes Mellitus, Experimental ,03 medical and health sciences ,Mice ,0302 clinical medicine ,Oral administration ,Diabetes mellitus ,Hyperlipidemia ,medicine ,Animals ,Depression (differential diagnoses) ,Neuroinflammation ,Inflammation ,Dose-Response Relationship, Drug ,business.industry ,Depression ,Tumor Necrosis Factor-alpha ,nutritional and metabolic diseases ,medicine.disease ,Streptozotocin ,Tail suspension test ,030227 psychiatry ,Hindlimb Suspension ,Hydroxymethylglutaryl-CoA Reductase Inhibitors ,Inflammation Mediators ,business ,030217 neurology & neurosurgery ,medicine.drug - Abstract
Depression is a chronic and progressive syndrome and commonly associated with several neuropsychiatric comorbidities, of which depression is the most studied. It has been demonstrated that statins also have anti-inflammatory and immunomodulatory properties, which being explored for potential benefits in depression. However, the role of statins in the treatment of diabetes-related depression has not been well examined. Herein, we investigated the effects of atorvastatin on depressive behaviors and neuroinflammation in streptozotocin-induced diabetic mice. Our data indicated that oral administration of atorvastatin at 10 or 20 mg/kg for 3 weeks markedly ameliorated diabetes-associated depressive behaviors reflected by better performance in sucrose preference test (SPT), tail suspension test (TST), and novelty-suppressed feeding test (NSFT). The study further showed that atrovastatin decreased the expression of nucleus NF-κB p65 expression and ameliorated neuroinflammatory responses in prefrontal cortex as evidenced by less Iba-1-positive cells and lower inflammatory mediators including IL-1β and TNF-α. As expected, atorvastatin-treated diabetic mice exhibited significant improvement of hyperlipidemia rather than hyperglycemia. These results suggest that atorvastatin has the potential to be employed as a therapy for diabetes-related depression.
- Published
- 2019